Western medicals continues with leaps and bounds

 

 Japan has made history by approving the world's first practical viral oncology drug, which uses a genetically modified version of the common cold virus to aggressively destroy cancer cells.

And the science behind it is remarkable.

The treatment, called Telomelysin, was developed by Oncolys BioPharma, a medical startup originating from Okayama University.
It uses a modified adenovirus designed to target cancer.

Once inside malignant esophageal tumor cells, the virus multiplies and causes those cells to rupture, while the treatment is designed to limit damage to healthy tissue.

The approval marks a major step for a completely different way of fighting cancer.

Instead of relying only on conventional treatments, researchers are turning viruses themselves into weapons against tumors.
Commercial distribution has now begun from Kobe's medical district.

It is not a universal cancer cure, but the technology could open another path in cancer treatment.